Larimar Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview

Larimar Therapeutics

08/03/2024 12:36

* Larimar Therapeutics Inc  LRMR.OQ   LRMR.O  is expected
to show
no change in quarterly revenue when it reports  results on March
12 (estimated) for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Larimar Therapeutics Inc
is
for a loss of 25 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Larimar
Therapeutics Inc is $25.00​, above​ its last closing price
of $10.92. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.21       -0.22      -0.21     Beat    6
 Jun. 30 2023  -0.18       -0.19      -0.19     Met     2.6
 Mar. 31 2023  -0.25       -0.25      -0.15     Beat    39​
 Dec. 31 2022  -0.22       -0.27      -0.21     Beat    22.9
 ​​Sep.        -0.30       -0.42      -0.37     Beat    11.9
 30 2022                                                
 Jun. 30 2022  -0.49       -0.57      -0.47     Beat    18​
 Mar. 31 2022  -0.51       -0.51      -0.49     Beat    3.9
 Dec. 31 2021  -0.76       -0.72      -0.50     Beat    30.2
 This summary was machine generated March 8 at 12:36 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)